search
Back to results

Microbiota Transplantation for Radiation Enteritis

Primary Purpose

Radiation Enteritis

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Selective Microbiota Transplantation (SMT)
Fecal Microbiota Transplantation (FMT)
Sponsored by
The Second Hospital of Nanjing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radiation Enteritis focused on measuring Gut Microbiota, Radiation Enteritis, Selective Microbiota Transplantation, Fecal Microbiota Transplantation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. age ≥18 years old;
  2. Radiation enteritis diagnosed by colonoscopy after finishing radiotherapy.

Exclusion Criteria:

  1. Patients who were pregnant or nursing;
  2. Patients who were unable or unwilling to undergo a gastroscopy;
  3. Patients who had gastrointestinal infection;
  4. Patients with cardiopulmonary failure.

Sites / Locations

  • Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Selective Microbiota Transplant (SMT)

Fecal Microbiota Transplantation (FMT)

Arm Description

Patients undergo once SMT a day for three consecutive days.

Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.

Outcomes

Primary Outcome Measures

Change of toxicity grade
The change of toxicity grade according to the RTOG/EORTC toxicity scale at 4 weeks after SMT

Secondary Outcome Measures

Scores of gastrointestinal symptoms
Gastrointestinal symptoms will be evaluated according to NCI-CTC 5.0
Karnofsky Performance Status (KPS) scale
Changes in functional status of patients will be assessed according to the Karnofsky Performance Status (KPS) scale (ranging from 0 [dead] to 100 [normal activity, no evidence of disease])

Full Information

First Posted
January 7, 2018
Last Updated
October 30, 2019
Sponsor
The Second Hospital of Nanjing Medical University
Collaborators
Fuzhou General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03516461
Brief Title
Microbiota Transplantation for Radiation Enteritis
Official Title
Efficacy and Safety of Selective Microbiota Transplantation and Fecal Microbiota Transplantation in Radiation Enteritis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 7, 2018 (Actual)
Primary Completion Date
December 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Second Hospital of Nanjing Medical University
Collaborators
Fuzhou General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Radiation enteritis is one of the most feared complications after abdominal or pelvic radiation therapy.The gut microbiota is considered to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body metabolism. Evidence from animal studies demonstrated the link between intestinal bacteria and radiation enteritis. This clinical trial aims to evaluate the efficacy and safety of selective microbiota transplantation (SMT) and fecal microbiota transplantation (FMT) for radiation enteritis.
Detailed Description
The present clinical trial aims to re-establish a gut functionality state of intestinal flora through selective microbiota transplantation (SMT) or fecal microbiota transplantation (FMT) for radiation enteritis (RE). FMT is the whole profile of fecal microbiota transplantation. SMT is the intermediate composition of bacteria between traditional probiotics and whole profile of microbiota; it aims to stimulate the efficiency of fecal microbiota transplantation. At enrollment, "Shared Decision Making" intervention was applied to support patient involvement in making health decisions. Patients have opportunity to choose selective microbiota transplantation (SMT) or fecal microbiota transplantation (FMT). Patients will receive follow-up for at least 4 weeks. Blood test, endoscopy and questionnaire will be used to access participants at study start and at study completion. Fecal microbiota compositions, blood and urinary metabolic profiles of patients will be analyzed to assess associated microbial changes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiation Enteritis
Keywords
Gut Microbiota, Radiation Enteritis, Selective Microbiota Transplantation, Fecal Microbiota Transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Selective Microbiota Transplant (SMT)
Arm Type
Experimental
Arm Description
Patients undergo once SMT a day for three consecutive days.
Arm Title
Fecal Microbiota Transplantation (FMT)
Arm Type
Experimental
Arm Description
Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
Intervention Type
Procedure
Intervention Name(s)
Selective Microbiota Transplantation (SMT)
Other Intervention Name(s)
SMT
Intervention Description
Selective microbiota transplantation for patients via nasointestinal tube (once per day for 3 days)
Intervention Type
Procedure
Intervention Name(s)
Fecal Microbiota Transplantation (FMT)
Other Intervention Name(s)
FMT
Intervention Description
Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy (once per day and no more than 3 times)
Primary Outcome Measure Information:
Title
Change of toxicity grade
Description
The change of toxicity grade according to the RTOG/EORTC toxicity scale at 4 weeks after SMT
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Scores of gastrointestinal symptoms
Description
Gastrointestinal symptoms will be evaluated according to NCI-CTC 5.0
Time Frame
4 weeks
Title
Karnofsky Performance Status (KPS) scale
Description
Changes in functional status of patients will be assessed according to the Karnofsky Performance Status (KPS) scale (ranging from 0 [dead] to 100 [normal activity, no evidence of disease])
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age ≥18 years old; Radiation enteritis diagnosed by colonoscopy after finishing radiotherapy. Exclusion Criteria: Patients who were pregnant or nursing; Patients who were unable or unwilling to undergo a gastroscopy; Patients who had gastrointestinal infection; Patients with cardiopulmonary failure.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Faming Zhang, MD; PHD
Phone
086-25-58509883
Email
fzhang@njmu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Faming Zhang, MD; PHD
Organizational Affiliation
The Second Hospital of Nanjing Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Faming Zhang, MD, PhD
Phone
086-25-58509883
Email
fzhang@njmu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
28242755
Citation
Cui M, Xiao H, Li Y, Zhou L, Zhao S, Luo D, Zheng Q, Dong J, Zhao Y, Zhang X, Zhang J, Lu L, Wang H, Fan S. Faecal microbiota transplantation protects against radiation-induced toxicity. EMBO Mol Med. 2017 Apr;9(4):448-461. doi: 10.15252/emmm.201606932.
Results Reference
background
PubMed Identifier
22183182
Citation
Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):88-96. doi: 10.1038/nrgastro.2011.244.
Results Reference
background
PubMed Identifier
25168749
Citation
Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, Ji G, Wang X, Wu K, Fan D, Zhang F. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015 Jan;30(1):51-8. doi: 10.1111/jgh.12727.
Results Reference
background
PubMed Identifier
24599929
Citation
Ferreira MR, Muls A, Dearnaley DP, Andreyev HJ. Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. Lancet Oncol. 2014 Mar;15(3):e139-47. doi: 10.1016/S1470-2045(13)70504-7.
Results Reference
background
PubMed Identifier
29691757
Citation
Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24.
Results Reference
background
PubMed Identifier
18564125
Citation
Manichanh C, Varela E, Martinez C, Antolin M, Llopis M, Dore J, Giralt J, Guarner F, Malagelada JR. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol. 2008 Jul;103(7):1754-61. doi: 10.1111/j.1572-0241.2008.01868.x. Epub 2008 Jun 28.
Results Reference
background
PubMed Identifier
25955845
Citation
Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015.
Results Reference
background
PubMed Identifier
25600706
Citation
Kim YS, Kim J, Park SJ. High-throughput 16S rRNA gene sequencing reveals alterations of mouse intestinal microbiota after radiotherapy. Anaerobe. 2015 Jun;33:1-7. doi: 10.1016/j.anaerobe.2015.01.004. Epub 2015 Jan 16.
Results Reference
background
PubMed Identifier
12190202
Citation
Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C, Famularo G. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002 Aug;97(8):2150-2. doi: 10.1111/j.1572-0241.2002.05946.x. No abstract available.
Results Reference
background
PubMed Identifier
24200199
Citation
Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014 Oct;33(5):761-7. doi: 10.1016/j.clnu.2013.10.015. Epub 2013 Oct 24.
Results Reference
background
PubMed Identifier
25304789
Citation
Nascimento M, Aguilar-Nascimento JE, Caporossi C, Castro-Barcellos HM, Motta RT. Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: a randomized, double-blind, placebo-controlled pilot trial. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):289-95. doi: 10.1016/j.ijrobp.2014.05.049.
Results Reference
background
PubMed Identifier
32044171
Citation
Ding X, Li Q, Li P, Chen X, Xiang L, Bi L, Zhu J, Huang X, Cui B, Zhang F. Fecal microbiota transplantation: A promising treatment for radiation enteritis? Radiother Oncol. 2020 Feb;143:12-18. doi: 10.1016/j.radonc.2020.01.011. Epub 2020 Feb 7.
Results Reference
derived

Learn more about this trial

Microbiota Transplantation for Radiation Enteritis

We'll reach out to this number within 24 hrs